Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : BT524
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Phase III
Sponsor : Grifols International
Deal Size : $1,281.5 million
Deal Type : Acquisition
Details : This acquisition will significantly reinforce Grifols’ industry capabilities by enhancing its plasmaderived medicines access, pipeline Biotest is leading clinical trials on plasma-derived fibrinogen (BT524) to treat congenital and acquired disorders.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Undisclosed
September 17, 2021
Lead Product(s) : BT524
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase III
Sponsor : Grifols International
Deal Size : $1,281.5 million
Deal Type : Acquisition
Reset All
